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Abstract
Background: Multiple clinical conditions are associated with cerebral hypoxia/ischaemia and thereby an increased
risk of hypoxic-ischaemic brain injury. Cerebral near-infrared spectroscopy monitoring (NIRS) is a tool to monitor
brain oxygenation and perfusion, and the clinical uptake of NIRS has expanded over recent years. Specifically, NIRS
is used in the neonatal, paediatric, and adult perioperative and intensive care settings. However, the available
literature suggests that clinical benefits and harms of cerebral NIRS monitoring are uncertain. As rates of clinically
significant hypoxic-ischaemic brain injuries are typically low, it is difficult for randomised clinical trials to capture a
sufficiently large number of events to evaluate the clinical effect of cerebral NIRS monitoring, when focusing on
specific clinical settings. The aim of this systematic review will be to evaluate the benefits and harms of clinical care
with access to cerebral NIRS monitoring versus clinical care without cerebral NIRS monitoring in children and adults
across all clinical settings.
Methods: We will conduct a systematic review with meta-analysis and trial sequential analysis. We will only include
randomised clinical trials. The primary outcomes are all-cause mortality, moderate or severe persistent cognitive or
neurological deficit, and proportion of participants with one or more serious adverse events. We will search CENT
RAL, EMBASE, MEDLINE, and the Science Citation Index Expanded from their inception and onwards. Two reviewers
will independently screen all citations, full-text articles, and extract data. The risk of bias will be appraised using the
Cochrane risk of bias tool version 2.0. If feasible, we will conduct both random-effects meta-analysis and fixed-effect
meta-analysis of outcome data. Additional analysis will be conducted to explore the potential sources of
heterogeneity (e.g. risk of bias, clinical setting).
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Discussion: As we include trials across multiple clinical settings, there is an increased probability of reaching a
sufficient information size. However, heterogeneity between the included trials may impair our ability to interpret
results to specific clinical settings. In this situation, we may have to depend on subgroup analyses with inherent
increased risks of type I and II errors.
Systematic review registration: PROSPERO CRD42020202986. This systematic review protocol has been submitted
for registration in the International Prospective Register of Systematic Reviews (PROSPERO) (http://
www.crd.york.ac.uk/prospero) on the 12th of October 2020 and published on the 12th of November 2020
(registration ID CRD42020202986).
Keywords: Systematic review, Cerebral NIRS monitoring, Cerebral oxygenation monitoring, Hypoxic-ischaemic brain
injury, Intensive care, Anaesthesia, Surgery, Neonatal intensive care, Meta-analysis, Trial sequential analysis
Background
Description of the condition
The brain depends on a constant supply of nutrients and
oxygen for structural integrity and function. Different
mechanisms such as low blood pressure, inadequate car-
diac output, hypoxaemia, and hypocapnia (decreased
carbon dioxide in the blood) may lead to inadequate
blood supply to the brain (hypoxia/ischaemia) [1–4] and
ultimately to brain injury [3–7]. Typical patients with
hypoxic-ischaemic brain injury are those with stroke,
those resuscitated after cardiac arrest, those rescued
from severe casualties, those with perinatal asphyxia, or
those with critical cardiopulmonary organ failure [8–12].
Loss of consciousness occurs in seconds after cardiac
arrest and injurious processes from lack of oxygen occur
within minutes [13]. In drowning or choking, this
process may take longer due to the reservoir of oxygen
in the pulmonary alveoli [14]. There are differences be-
tween the loss of respiration and oxygen supply and the
loss of circulation and delivery of oxygen to tissues.
However, from the cellular perspective, the common ef-
fect is a critical reduction in local tissue oxygen
concentration, reduced mitochondrial oxidative phos-
phorylation, reduced intracellular ATP concentration,
reduced Na-K pumping across the plasma membrane,
loss of membrane potential, and from there on a range
of destructive (and reparative) processes starts with re-
sultant tissue damage [13].
Brain injury, defined as the acute reaction to a
hypoxic-ischaemic insult can be diagnosed by neuro-
logical examination, electrophysiology methods, or func-
tional tests [15, 16]. Brain injury may lead to brain
damage that can be diagnosed by brain imaging [17–19].
Brain damage may lead to more or less permanent
neurological or cognitive impairment, depending on lo-
cation, extent, and compensatory mechanisms [12, 19].
While brain imaging can be used to detect brain damage
and define clinically relevant outcomes, later neuro-
logical examinations, functional testing, or question-
naires can be used to define relevant patient outcomes.
Full recovery may occur both in children and adults,
while more subtle impairment may only become evident
with long-term follow-up — which especially holds true
in newborns.
Clinical settings with elevated risk of hypoxic-ischaemic
brain injury
Anaesthesia and surgery
Cerebral oxygenation may drop due to hypoxaemia,
hyperventilation, and/or hypotension [20–23]. This often
happens to a mild degree but may be severe due to com-
plications of anaesthesia or the surgical procedure itself.
Cardiac surgery under cardiac arrest or during cardio-
pulmonary bypass carries specific risks for cerebral oxy-
genation impairment as well. General recovery after
anaesthesia and surgery can be protracted, may involve
an element of cognitive dysfunction, and occasionally
frank neurological deficit appears [24–27].
Intensive care
Critical illness with respiratory failure or circulatory
shock is associated with brain injury or dysfunction [28,
29]. Mental and cognitive recovery after intensive care
can be protracted, with occasionally unexpected neuro-
logical deficits. Current research is focusing on patho-
genesis, prediction, and prevention of these outcomes
[30–32].
Preterm birth
Newborns adapt to extra-uterine life during the first mi-
nutes, hours, and days of life [33]. Filling of the lungs
with air, establishing respiration and pulmonary blood
flow, and closing of the foramen ovale and the ductus
arteriosus all constitute components of this transition
[4]. In preterm neonates, this challenge is compounded
by immature lungs, inadequate surfactant production,
and myocardial immaturity with limited diastolic as well
as systolic function [4]. In extremely preterm infants,
this process often requires cardiorespiratory support,
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and in spite of this, neurodevelopmental impairment is
common [34].
Monitoring of cerebral oxygenation
Direct monitoring of cerebral oxygenation is not routine
during general anaesthesia [35] or in the intensive care unit
[36, 37]. However, clinical uptake is growing, especially dur-
ing cardiac and aortic surgery [38–40] and in paediatric
[36] and neonatal intensive care [37]. Several cerebral oxy-
genation monitoring methods are available: jugular venous
blood sampling or catheter-based oximetry to measure
cerebro-venous oxygen saturation, oxygen electrodes to
measure tissue oxygen tension, or near-infrared spectros-
copy (NIRS) to measure mixed arterio-venous (‘tissue’) oxy-
gen saturation [41]. Cerebral NIRS has the distinct
advantage of being non-invasive, theoretically with few ad-
verse effects, and is applicable in almost all patients [42].
The theoretical pros and cons of monitoring cerebral
oxygenation
The question is, if monitoring of cerebral oxygenation
has added value for the patient, i.e. if it contributes to a
better clinical outcome when compared with routine
monitoring [43]. As the pathophysiology of hypoxic/is-
chaemic brain injury is well established, safeguarding
brain oxygenation should facilitate primary prevention
of brain injury. The delivery of oxygen to tissue depends
on the interplay of many factors, such as the reactions of
cerebral vasculature to hypotension and hypoxia, as well
as the oxygen carrying capacity of the blood, haemoglo-
bin affinity for oxygen, and blood viscosity [44, 45]. The
oxygen balance in tissue also depends on oxygen de-
mand that may be increased in fever or during seizures,
among other conditions [46].
On the other hand, measurements of cerebral oxygen-
ation are not always accurate and may sometimes be er-
roneous [47, 48], and thresholds for intervention may be
poorly defined [49]. Moreover, monitoring entails risks
of overtreatment and undertreatment. For example, if
FiO2 is unnecessarily increased due to hypoxic cerebral
oxygenation values, an increased risk of bronchopul-
monary dysplasia and retinopathy of prematurity in pre-
term infants may follow [50, 51]. In the SafeBoosC-II
trial, comparing treatment guided by cerebral NIRS
monitoring versus treatment and monitoring as usual in
extremely preterm infants, an increased incidence of
bronchopulmonary dysplasia and retinopathy of prema-
turity was seen in the experimental group [52]. Monitor-
ing also has its costs in terms of equipment and
clinicians’ time and attention.
Randomised clinical trials of a complex intervention
The gold standard for testing the benefits and harms of
diagnostic tests (NIRS) and following treatments
(reactions to improve cerebral oxygenation) is rando-
mised clinical trials [53, 54]. The diagnostic method
must be connected to an intervention to produce a clin-
ical benefit. For a monitoring technique such as cerebral
NIRS monitoring, in addition to the complexities of de-
fining thresholds for action, as well as defining the range
of potential interventions, there is also the issue of time.
It is thus difficult precisely to define the intervention
that is tested in a trial assessing the effects of NIRS, and
randomised clinical trials will depend on the clinical
skills of the clinicians caring for patients in the experi-
mental as well as in the control group. Potentially, the
control group can be monitored, but with a blinded
screen, which allows retrospective analysis of options for
brain-dedicated interventions.
Previous evidence on the use of cerebral NIRS monitoring
in different clinical settings
According to our knowledge, three systematic reviews
with meta-analysis have evaluated the use of cerebral
NIRS monitoring to guide clinical care compared to
clinical care without access to cerebral NIRS monitoring,
in different clinical settings, with a goal of promoting
neuroprotection [38, 39, 55].
One review evaluated the use of cerebral NIRS moni-
toring in patients undergoing cardiopulmonary bypass
[38]. It included 1466 adults across ten trials and found
no significant difference in mortality or stroke between
experimental and control participants [38]. However, the
number of events were low. The number of deaths in
the experimental group were 6/298 participants versus
10/310 participants in the control group. For strokes,
the numbers were 9/567 participants in the experimental
group versus 9/571 participants in the control group
[38]. The review did not use sequential methods (e.g.
trial sequential analysis) to control risks of type I and
type II errors [56]. Furthermore, several of the included
trials were assessed at high risk of bias due to unclear in-
formation on blinding of clinical personnel, participants,
and outcome assessors, insufficient reporting of data
completeness for the primary outcome, and selective
reporting bias with only one trial having published a
protocol. The GRADE assessment showed low or very
low certainty of evidence for all outcomes [38]. Thus,
the authors concluded that the existing evidence does
not indicate a significant clinical benefit of cerebral
NIRS monitoring during cardiac surgery and that there
is a need for additional, low risk of bias randomised clin-
ical trials to determine the clinical effect of the interven-
tion [38].
A Cochrane review from 2018 also evaluated the use
of cerebral NIRS monitoring in the perioperative setting
[39]. This review included randomised clinical trials
evaluating cerebral NIRS monitoring during all types of
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surgery. The review included 1822 adult participants
across 15 trials. No significant differences were found
between experimental and control participants, for either
mortality, postoperative stroke, postoperative delirium,
or postoperative cognitive dysfunction. However, as with
the systematic review on cardiopulmonary bypass [38],
the number of events were low, and only one to six trials
were included in the meta-analysis for each outcome (1/
195 versus 2/195 deaths, 1/120 versus 4/120 postopera-
tive strokes, 9/94 versus 14/96 episodes of postoperative
delirium, and 13/24 versus 27/33 episodes of postopera-
tive cognitive dysfunction after one week of surgery, in
the experimental and control group) [39]. This review
also did not use sequential methods (e.g. trial sequential
analysis) to control risks of type I and type II errors [56].
The authors graded the certainty of evidence as low to
moderate, mainly due to uncertainty regarding allocation
concealment, potential conflict of interest from industry
sponsorship, unclear blinding status, missing participant
data, and imprecision. Based on the review results, the
authors conclude that it is uncertain whether cerebral
NIRS has a clinical benefit as a perioperative monitoring
tool, due to low quality of evidence as well as low num-
ber of events [39].
An additional Cochrane review from 2017 evaluated
the use of cerebral NIRS monitoring in very preterm in-
fants [55]. The review included only one randomised
clinical trial with a total of 166 participants and found
no significant differences between the experimental and
control participants for neither mortality (12/86 versus
20/80), mild-moderate brain injury by ultrasound (49/80
versus 33/77), or severe brain injury by ultrasound (10/
80 versus 18/77) [55]. The trial, however, was not pow-
ered to detect a relevant difference on any of these clin-
ical outcomes. Due to the small sample size, lack of
group allocation blinding, and the surrogate outcomes
being indirectly linked to the clinical outcomes, the au-
thors graded the certainty of evidence as very low to
low. The review authors concluded that, based on the
available evidence, the effect of cerebral NIRS monitor-
ing in preterm infants cannot be established and that
there is a need for additional large-scale randomised
clinical trials with clinically relevant primary outcomes
[55].
The characteristics of these three reviews are summa-
rized in Table 1.
The motivation and aim of the present meta-analysis
The primary purpose of monitoring of cerebral oxygen-
ation is the prevention of hypoxic/ischaemic brain in-
jury. The rates of clinically significant hypoxic/ischaemic
brain injury, however, are typically low, and large num-
bers of participants are needed to exclude effects of im-
portance [56]. Therefore, the purpose of this systematic
review with meta-analysis and trial sequential analysis is
to evaluate the beneficial and harmful effects of clinical
care with access to cerebral NIRS monitoring versus
clinical care without access to cerebral NIRS monitoring,
in children and adults across all clinical settings. Since
the primary purpose of NIRS monitoring is prevention
of brain injury, the majority of the chosen outcomes fo-
cuses on this.
Methods
This protocol is in adherence with the Preferred Report-
ing Items for Systematic reviews and Meta-Analyses for
Protocols (PRISMA-P) statement [57, 58] (see checklist
in Additional file 1). This protocol has been registered
within the International Prospective Register of System-
atic Reviews (PROSPERO) database (registration ID
CRD42020202986) [59, 60].
Eligibility criteria
Studies will be selected according to the following
criteria.
Types of studies
We will include randomised clinical trials, irrespectively
of publication status, publication type, publication year,
or written language. Cluster randomised trials and the
first part, before cross-over, of randomised cross-over
trials will also be included. Quasi-randomised studies
and other studies that are not randomised clinical trials
will be excluded.
Types of participants
We will include adults and children of all ages, including
neonates, irrespectively of sex and comorbidities.
Types of interventions
The experimental intervention will be cerebral NIRS
monitoring to guide clinical care, irrespectively of the
length of the intervention period and clinical setting.
The control intervention will be no access to cerebral
NIRS monitoring. In some trials, participants in the con-
trol group will have received cerebral NIRS monitoring
to collect data on cerebral oxygenation values during the
trial, but where the oxygenation values were unavailable
to the clinical staff. In such trials, the control interven-
tion will also be defined as no access to cerebral NIRS
monitoring, as this additional monitoring to collect data,
was not a part of the control intervention.
Any co-interventions can be accepted but only if the
co-intervention is planned to be delivered similarly in
both the experimental and control group.
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Outcomes
Primary outcomes
1. All-cause mortality at maximal follow-up.
2. Moderate or severe, persistent cognitive or
neurological deficit, significantly affecting daily life,
at maximum follow-up (e.g. modified Rankin score
of three or higher [61], Gross Motor Function Clas-
sification System level two or higher [62], or Bayley
Scale of Infant Development score below minus two
standard deviations at 2 years or later [63]). If sev-
eral of such outcomes are reported, then we will
choose the outcome with the highest proportion re-
ported in each trial.
3. Proportion of participants with one or more serious
adverse events. We will define a serious adverse
event as any untoward medical occurrence that
resulted in either death, was life-threatening, jeopar-
dised the participant, was persistent, led to signifi-
cant disability, led to hospitalisation, or led to
prolonged hospitalisation [64]. As we expect the
trialists’ reporting of serious adverse events to be
heterogeneous and not strictly according to the
International Committee of Harmonization-Good
Clinical Practice (ICH-GCP) recommendations, we
will include the event as a serious adverse, if the
trialist either: (a) used the term ‘serious adverse
event’ but not refer to ICH-GCP [64] or (b) re-
ported the proportion of participants with an event
we consider to full-fill the ICH-GCP definition (e.g.
myocardial infarction or hospitalisation). If several
of such outcomes are reported, then we will choose
the outcome with the highest proportion reported
in each trial.
Secondary outcomes
1. Mild, moderate or severe, temporary or persistent,
cognitive or neurological deficit as defined by the
trialists (e.g. postoperative delirium, postoperative
cognitive decline, or Bayley Scale of Infant
Development score below minus one standard
Table 1 Overview of previous systematic reviews and meta-analyses evaluating the effect of clinical care guided by cerebral NIRS
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cPVL cystic periventricular leukomalacia, IVH intraventricular haemorrhage, NIRS near-infrared spectroscopy, RCTs randomised clinical trials, POCD postoperative
cognitive decline, POD postoperative delirium, TCI transient cerebral ischaemia
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deviations [63]). If several of such outcomes are
reported, then we will choose the outcome with the
highest proportion reported in each trial.
2. Quality of life defined as any validated continuous
outcome scale used by the trialists at maximum
follow-up.
3. Any evidence of brain damage on imaging as
defined by the trialists at maximal follow-up. If sev-
eral of such outcomes are reported, then we will
choose the outcome with the highest proportion re-
ported in each trial.
4. Proportion of participants with one or more
adverse events defined as an untoward medical
occurrence that did not necessarily have had to
have a causal relationship with the intervention and
which is also non-serious [64].
Exploratory outcomes
1. Any evidence of a negative impact on the brain as
defined by the trialists (including mild, moderate or
severe, temporary or persistent cognitive or
neurological deficits, evidence of brain damage on
imaging, or evidence of brain damage on
electrophysiological monitoring). If several of such
outcomes are reported, then we will choose the
outcome with the highest proportion reported in
each trial.
2. Individual serious adverse events [64]
3. Individual adverse events [64]
Information sources and search strategy
Trials will be identified through systematic searches
within the following databases, from inception and on-
wards: Cochrane Central Register of Controlled Trials
(CENTRAL), EMBASE, MEDLINE, and Science Citation
Index Expanded. No language or time restriction will be
applied. The reference lists of all relevant trials will be
checked as well.
A detailed search strategy for MEDLINE Ovid as well
as the search results can be found in ‘Additional file 2’.
The search strategy will be adapted to other databases.
Searching other resources
As an additional search tool, we will search for unpub-
lished and ongoing trials at clinicaltrials.gov and the fol-
lowing medical device companies websites: Medtronic,
Minneapolis, MN, USA; NIRO, Hamamatsu, Hamama-
tsu City, Japan; CAS Medical, Branford, CT, USA; Nonin
Medical, Plymouth, MN, USA; Masimo, Irvine, CA,
USA; Enginmed, Suzhou, China; and Oxyprem, Zürich,
Switzerland. Furthermore, we will also identify ongoing
relevant trials through trial registers in Europe and USA
including clinicaltrials.gov.
For ClinicalTrials.gov, we will conduct the following
search:
Condition or disease: (Near-infrared spectroscop*) OR
(Near-infrared spectromet*) OR (Near infrared spectro-
scop*) OR (NIR spectromet*) OR (NIR spectroscop*)
OR (NIRS) OR (Oxygenati*) OR (Oxygen saturation) OR
(Oximetr*) OR (Cerebral perfusion) OR (Cerebral
saturation)
Other terms: (Randomized) or (Randomised)
Study type: Interventional Studies (Clinical trials)
Study results: all studies
Data collection and analysis
Selection of studies
All trials that are identified during the literature search
will be uploaded to EndNote (Clarivate, Philadelphia,
PA, USA). Two authors (MLH and SHS) will screen the
titles and abstracts of the identified studies. If a study is
deemed potentially relevant by either one of the two au-
thors, the full text will be retrieved and assessed for eli-
gibility by the same two authors. If ineligible, the reason
for exclusion will be documented. If there is a disagree-
ment between the two authors regarding eligibility or in-
eligibility, a third author (JCJ) will make the final
decision of inclusion or exclusion. Eligible trials will be
included in the systematic review and a Preferred
Reporting Items for Systematic Reviews and Meta-
Analysis (PRISMA) flow diagram will be included as
well. Also, a table displaying the characteristics of ex-
cluded studies will be presented in the final systematic
review [65]. Analysis of cluster randomised trials and the
first part, before cross-over, of randomised cross-over
trials, will be handled as depicted in The Cochrane
Handbook for Systematic Reviews of Interventions [66].
Data extraction and management
Once the relevant trials have been included, data extrac-
tion will be conducted by the two authors MLH and
SHS independently. Any disagreements will be discussed
in the author group and a final decision will be made.
The following data will be extracted from each study:
1. General information: title, author(s), year of
publication, language of publication, funding
sources, and potential conflicts of interest
2. Methodology: study design, clinical setting,
inclusion and exclusion criteria, type of
interventions, cerebral NIRS monitoring unavailable
for clinical staff in the control group, outcome
measures, and time of outcome assessment
3. Sample size: number of participants meeting the
criteria for inclusion
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We will use specific data extraction forms designed for
this purpose. If some of the relevant data is not available
in the study report or publication, e.g. if the study does
not report all of the pre-specified outcomes, the trialists
will be contacted and asked if they can provide such
data. The correspondence with the trialists will be in-
cluded in the systematic review as an appendix.
Outcome classification
The two authors MLH and SHS will present all the rele-
vant, extracted outcome measures from each included
trial to the authors GG and JCJ, without revealing the
number of outcome events in the experimental and con-
trol group. GG and JCJ will then classify the outcomes
according to the primary, secondary, and exploratory
outcome definitions in this protocol. If there is disagree-
ment between GG and JCJ on any outcome classifica-
tion, a fifth author (CG) will make the final decision.
Assessment of risk of bias in included studies
Randomised clinical trials with certain methodological
flaws carry an increased risk of bias [67–72]. Such meth-
odological flaws increase the likelihood that the trialists
will come to the wrong conclusion by over- or under-
estimating effect sizes [73]. Therefore, it is important to
assess the risk of bias in trials included in a systematic
review [65]. Based on the Cochrane risk of bias tool —
version 2 (RoB 2) [74] described in The Cochrane Hand-
book for Systematic Reviews of Interventions [75], we
will assess the risk of bias for the following domains: (1)
bias arising from the randomisation process, (2) bias due
to deviation from intended interventions, (3) bias due to
missing outcome data, (4) bias in measurements of out-
comes, and (5) bias in selection of the reported results.
Risk of bias assessment of the included studies will be
conducted by the two authors MLH and SHS, who inde-
pendently will transfer data into the Stata file. Any dis-
agreement between their assessments will be discussed
and, if necessary, a final decision will be made by a third
author (JCJ).
Bias arising from the randomisation process
A trial will be considered at low risk of bias if the alloca-
tion sequence was adequately concealed (e.g. performed
by an on-site locked computer, a central independent
unit or sealed, identical envelopes), and there are no
baseline imbalances between the experimental and con-
trol group (if any appeared, they must be compatible
with chance), and the allocation sequence generation
was adequate (e.g. generated by a computer random
numbers generator, a random numbers table, tossing a
coin, shuffling cards or drawing lots - the latter three
methods will only be considered low risk of bias if the
sequence generation was conducted by an independent
person with no involvement in the trial), or if a descrip-
tion of the method for allocation sequence generation is
missing.
A trial will be considered of some concerns if the allo-
cation sequence was adequately concealed and there is a
problem with the method of allocation sequence gener-
ation, or baseline imbalances suggest a problem with the
randomisation process, or if the method for allocation
concealment was not described for the trial, and baseline
imbalances across intervention groups appear to be by
chance, or if no information is available to answer any of
the signaling questions.
A trial will be considered at high risk of bias if investi-
gators were aware of the allocation sequence [68], or if
the method for allocation concealment was not de-
scribed, and if baseline imbalance suggest a problem
with the randomisation process.
Furthermore, trials where the generation was not at
random, or quasi-randomised, will be considered high
risk of bias and excluded from the review [71, 76]
Bias due to deviation from intended interventions
A trial will be considered at low risk of bias if partici-
pants and clinical staff — and parents in paediatric trials
— were unaware of the group allocation during the trial,
or if they were aware of the group allocation during the
trial, but any deviation from the intended intervention
reflected normal clinical practice, or if they were aware
of group allocation, but any deviation from the intended
intervention was unlikely to influence the outcomes, and
no trial participants were analysed on the basis of the re-
ceived intervention, instead of on the basis of their ran-
domised allocation group.
A trial will be considered of some concerns if partici-
pants and clinical staff — and parents in paediatric trials
— were aware of group allocation, and no information is
available regarding deviations from normal clinical prac-
tice, which potentially could impact the outcomes and
the deviations from clinical practice were imbalanced be-
tween the intervention groups, or some trial participants
were analysed on the basis of the received intervention
instead of on the basis of randomised allocation group,
but it was deemed as insufficient to significantly alter
the intervention effect estimate.
A trial will be considered at high risk of bias if partici-
pants and clinical staff — and parents in paediatric trials
— were aware of group allocation [73, 77], and there
were deviations from intended interventions which were
unbalanced between the intervention groups, and likely
to affect the outcomes, or some participants were ana-
lysed on the basis of the received intervention instead of
on the basis of randomised group allocation, and it was
deemed as sufficient to significantly alter the interven-
tion effect estimate.
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Bias due to missing outcome data
A trial will be considered at low risk of bias if there is no
missing outcome data, or if the proportion of missing
outcome data is similar between the intervention groups,
and the reasons for missing outcome data are similar, or
if there is evidence that the missing outcomes do not
make an important difference to the estimate of the
intervention effect (e.g. sensitivity analyses such as ‘best-
worst, worst-best’ case scenario analysis).
A trial will be considered of some concerns if the
amount of missing outcome data is unclear, or there is
unclear information regarding the proportion of missing
data between intervention groups, and reason for miss-
ing outcome data between intervention groups is un-
clear, and there is no evidence that the missing outcome
data do not make an important difference to the esti-
mate of the interventions effect (e.g. lack of sensitivity
analyses such as ‘best-worst, worst-best’ case scenario
analysis).
A trial will be considered at high risk of bias if the
amount of missing data is high (more than 5%), and
missing outcome data between the intervention groups
differ, or the reason for missing outcome data between
intervention groups differ, and there is no evidence that
the missing outcome data do not make an important dif-
ference to the estimate of the interventions effect (e.g.
lack of sensitivity analyses such as ‘best-worst, worst-
best’ case scenario analysis) [71].
Bias in measurement of outcomes
A trial will be considered at low risk of bias if the out-
come assessors were blinded to group allocation, or if
the outcome assessors were not blinded to group alloca-
tion, but it was deemed that knowledge of group alloca-
tion was unlikely to influence outcome assessment.
A trial will be considered of some concerns if there is
no available information to evaluate whether outcome
assessors were blinded to group allocation and if such
knowledge could influence outcome assessment.
A trial will be considered at high risk of bias if out-
come assessors were not blinded to group allocation and
it is deemed likely that knowledge of group allocation
was likely to influence outcome assessment [73, 78].
Bias in selection of the reported result
A trial will be considered at low risk of bias if the out-
come data reported are unlikely to have been selected
based on the results of multiple outcome measurements
(e.g. different scales to measure the outcome, multiple
assessors of the outcome, different time points for as-
sessment of the outcome) within the outcome domain,
and if the outcome data reported are unlikely to have
been selected based on the results from multiple out-
come analysis.
A trial will be considered of some concerns if it is un-
certain whether the outcome data reported have been
selected based on the results of multiple outcome mea-
surements (e.g. different scales to measure the outcome,
multiple assessors of the outcome, different time points
for assessment of the outcome) within the outcome do-
main or from multiple outcome analysis.
A trial will be considered at high risk of bias if the re-
ported outcome data are likely to have been selected
based on the results of multiple outcome measurements
(e.g. different scales to measure the outcome, multiple
assessors of the outcome, different time points for as-
sessment of the outcome) within the outcome domain or
from multiple outcome analysis.
Overall risk of bias
The included trials will be considered as overall in low risk
of bias or high risk of bias. A trial will be considered over-
all low risk of bias if the trial is judged as low risk of bias
in all the above domains. If the trial is considered at high
risk of bias, or to be of some concern, in any of the above
domains, the trial will be considered as overall in high risk
of bias. Within each trial, each outcome result will be
assessed for bias, based on the three domains ‘bias due to
missing outcome data’, ‘bias in measurements of out-
comes’, and ‘bias in selection of the reported result’. Thus,
we will be able to assess not only risk of bias in each trial,
but also for each outcome. Additionally, the Grading of
Recommendations, Assessment, Development and Evalu-
ation (GRADE) assessment will be used to assess the qual-
ity of the body of evidence for all outcomes and
summarized in a summary of findings table [79] (see the
section ‘Summary of findings table’ for a description of the
five considerations included in the GRADE assessment).
The primary conclusion will be based on the analysis
of our primary outcome results in all trials assessed as
having an overall low risk of bias [56].
Assessment of bias in conducting the systematic review
The systematic review will be conducted according to
this protocol. Any deviation in the conduct will be re-
ported in the section ‘Differences in the methodology
between protocol and review’ in the systematic review.
Measures of treatment effect
Dichotomous outcomes
For dichotomous outcomes we will calculate risk ratios
(RRs) with 95% confidence intervals (CIs) and trial se-
quential analysis-adjusted CIs [56, 80].
Continuous outcomes
For continuous outcomes, i.e. ‘Quality of Life’, we will
calculate the standardized mean difference with a 95%
CI and a trial sequential analysis-adjusted CI [56, 80].
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Handling missing data
We will use the intention-to-treat data from the in-
cluded trials for both dichotomous and continuous out-
comes. For trials with missing or unclear outcome data,
the trial authors will be contacted by MLH with JCJ as
‘cc’. The trial authors will be requested to provide miss-
ing outcome data or to elaborate on unclear outcome
data. All correspondence will be attached to the system-
atic review in an appendix. If it is not possible to obtain
missing outcome data, we will not impute the missing
data for the primary analysis. Instead, this will be done
in the sensitivity analyses.
Data synthesis
A descriptive table featuring the included trials’ key
characteristics and methodology will be reported, includ-
ing the following information: title, author(s), year of
publication, language of publication, funding sources,
potential conflicts of interest, study design, clinical set-
ting, inclusion criteria, exclusion criteria, types of inter-
vention, outcome assessment, time of outcome
assessment, and protocol status. All data analyses will be
conducted in STATA 16.1 (StataCorp LLC, College Sta-
tion, Texas, USA). The meta-analysis will be conducted
as recommended in the Cochrane Handbook for Sys-
tematic Reviews of Interventions [81]. For outcomes
where data is only available from one trial, the results
will be narratively described. If one or more of the in-
cluded trials reports on multiple intervention arms, we
will only include the relevant arms. Furthermore, the
population in the control group will be halved for such
studies, if two of the comparisons are included in the
meta-analysis. An eight-step procedure by Jakobsen
et al. will be used to assess if thresholds for statistical
and clinical significance are crossed [56].
Step one — meta-analysis
Both fixed-effect and random-effects meta-analyses will
be used to estimate the effect of the intervention [82,
83]. The most conservative results (highest P value) will
primarily be used and the less conservative result will be
used as sensitivity analysis [56].
Step two — assessment of heterogeneity
Statistical heterogeneity will be evaluated by using I2 sta-
tistics, with a threshold for significant heterogeneity at p
< 0.1 [84], and by visual inspection of forest plots. Clin-
ical heterogeneity will be assessed by evaluating the
characteristics of the included trials based on the PICO
model (Participants, Interventions, Comparisons, Out-
comes). Any signs of heterogeneity will be explored in
the subgroup analyses.
Step three — accounting for multiplicity
Since we report on three primary outcomes, a p value
below 0.025 will be considered statistically significant for
each of the primary outcomes [56].
Step four — trial sequential analysis
To control the risks of type I and II errors [85], all pri-
mary outcomes will undergo trial sequential analysis and
the required meta-analysis information size as well trial
sequential boundaries for benefit, harm, and futility will
be established [86]. If the required number of rando-
mised participants to achieve sufficient power is not
reached, the confidence interval for the point estimates
will be adjusted accordingly by the trial sequential ana-
lysis program [80, 86]. A relative risk reduction of 20%
will be used as the anticipated intervention effect for
each primary outcome, an alpha of 2.5% will be used as
the acceptable risk of type 1 errors and a beta of 10%
will be used as the acceptable risk of type 2 errors.
For cumulative Z-scores that reach below 50% of the
diversity-adjusted trial sequential analysis required infor-
mation size (or sample size), we will downgrade impreci-
sion by two levels for the GRADE assessments (see
section on ‘Summary of findings table’). For cumulative
Z-scores that reach between 50 and 100% of the
diversity-adjusted trial sequential analysis required infor-
mation size (or sample size), we will downgrade impreci-
sion by one level for the GRADE assessments. For
cumulative Z-scores that cross the monitoring boundar-
ies for benefit, futility, or harm, we will not downgrade
imprecision for the GRADE assessments.
Step five — Bayes factor
The Bayes factor [87] will be calculated for all primary
outcomes and 0.1 will be used as threshold for signifi-
cance [56]. An anticipated risk reduction of 20% will be
used when calculating the Bayes factor [56].
Step six — subgroup and sensitivity analysis
The following subgroup analyses will be conducted, if
possible:
1. Comparison of the intervention effect between trials
at overall low to high risk of bias
2. Comparison of the intervention effect between trials
assessing different clinical settings: neonatal
intensive care, paediatric intensive care, children
during surgery, adult intensive care, and adults
during surgery
3. Comparison of trials without support from the
medical device industry compared to trials at risk of
such support [69]
4. Comparison of trials where participants in the
control group underwent cerebral NIRS
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monitoring, but where the oxygenation values were
unavailable to the clinical staff, compared to trials
where participants in the control group did not
undergo cerebral NIRS monitoring at all
To quantify the potential impact of missing outcome
data, the following two sensitivity analysis will be con-
ducted on the three primary outcomes:
a. ‘Best-worst case’ scenario: we will assume that all
participants lost to follow-up in the experimental
group either died, suffered from ‘moderate or severe
persistent cognitive or neurological deficit’, or had
‘one or more serious adverse events’, while all par-
ticipants lost to follow-up in the control group ex-
perienced these events.
b. ‘Worst-best case’ scenario: we will assume that all
participants lost to follow-up in the experimental
group suffered died, suffered from ‘moderate or se-
vere persistent cognitive or neurological deficit’, or
had ‘one or more serious adverse events’, while all
participants lost to follow-up in the experimental
group did not experience any of these events.
Step seven — assessment of risk of publication bias
If at least ten trials are included in the meta-analysis, we
will create funnel plots and visually inspect them to as-
sess any potential publication bias. As an additional
measure, we will evaluate the funnel plot asymmetry by
conducting the Harbord test [88] for dichotomous out-
comes and the Egger test for continuous outcome [89].
Step eight — assessment of clinical significance
If the data analyses show statistically significant effects
of the intervention, we will also assess whether the re-
sults are clinically significant. The assessment of clinical
significance will be based on the definitions of minimal
important differences (see ‘Step four — trial sequential
analysis’) and the summary of findings table (see section
on ‘Summary of findings table’) as well as a thorough
evaluation of beneficial and harmful outcomes. Further-
more, we will calculate the number-needed-to-treat for
all dichotomised outcomes [56].
Summary of findings table
To present the findings for the pre-specified primary,
secondary and exploratory outcomes, we will create and
include a ‘Summary of findings’ table in the systematic
review as recommended in the Cochrane Handbook for
Systematic Reviews of Interventions [90]. The Grading
of Recommendations, Assessment, Development and
Evaluations (GRADE) approach will be used to assess
and rate the quality of the body of evidence, i.e. the cer-
tainty in the range of an effect estimate for all pre-
specified outcomes [79]. The GRADE approach evalu-
ates the body of evidence based on the five following
considerations: (1) risk of bias assessment [74, 91], (2)
heterogeneity or inconsistency of results [92], (3) impre-
cision of the effect estimates due to wide CIs [93], (4) in-
directness of evidence [94], and (5) publication and for-
profit bias [95]. Imprecision will be assessed using trial
sequential analysis [56]. To assess for-profit bias, we will
search for information regarding industry funding for
each trial and trial author. If a trial, or an author, is
sponsored by the industry, we will judge the trial as in
high risk of for-profit bias. To conduct the rating, we
will use the online tool GRADEpro software (www.
gradepro.org). The reasons for any up- or downgrading
of the certainty of evidence will be described and justi-
fied in details in the systematic review [90].
As we expect heterogeneity due to the various clinical
settings and wide age span of participants in the in-
cluded studies within this systematic review, we will also
create summary of findings tables for the subgroup ana-
lysis within each of the different clinical settings (e.g.
neonatal intensive care trials, paediatric intensive care




The present review has several methodological strengths.
First, the methodology is predefined and registered on
PROSPERO before any literature search has been con-
ducted, since this decreases the risk of selective outcome
reporting bias of the systematic review [96, 97]. Any
changes to the protocol originating during the peer-
review or systematic review process will be described in
the systematic review in the section ‘Differences in the
methodology between protocol and review.’ Second, the
protocol includes a thorough description of the method-
ology which relies on the principles and methods out-
lined in The Cochrane Handbook for Systematic
Reviews of Interventional Research, including a risk of
bias assessment of all included studies as a tool to con-
sider systematic errors [98]. Third, we plan to use the
eight-step procedure by Jakobsen et al. to assess statis-
tical and clinical significance for each of the pre-
specified outcomes, which increases the validity of the
systematic review [56]. The eight-step procedure in-
cludes Trial Sequential Analyses, which controls for ran-
dom errors by checking if a sufficient information size
has been reached [80] and whether the boundaries for
futility, benefit, or harm have been crossed [86]. These
analyses will assist us in determining the need for down-
grading due to imprecision. To increase transparency
and heighten the quality of the systematic review, we will
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also provide a section, outlining any deviation to this
protocol, in the final publication.
Limitations
Our review also has important methodological limita-
tions. During the last decade, clinical research of NIRS
monitoring has increased rapidly, primarily during sur-
gery but also in the intensive care setting [38, 39, 55].
Parallel to this, the clinical uptake of NIRS monitoring
has grown as well [36, 37]. As all randomised clinical tri-
als evaluating the use of cerebral NIRS monitoring to
guide clinical care, irrespectively of age or clinical set-
ting, are eligible for this systematic review, we expect to
include trials across various clinical fields. Since the
population and study setting will then differ between in-
cluded trials, there is a potential for both statistical and
clinical heterogeneity. We will therefore conduct sub-
group analyses on the different populations and clinical
settings, e.g. subgroup analyses on studies within neo-
natal intensive care, paediatric intensive care, adult in-
tensive care, and perioperative monitoring during
surgery. Another limitation is our broad outcome defini-
tions. Due to the expected heterogeneity in the included
trials and to obtain sufficient information size for the
meta-analysis, it is necessary to be pragmatic and, thus,
classify and pool the outcomes reported in the included
trials into broader outcomes (e.g. moderate or severe,
persistent cognitive or neurological deficit, significantly
affecting daily life). As the two authors, MLH and SHS,
who will conduct the data extraction, will be aware of
the number of events in the experimental and control
group for each outcome in the included trials, there is a
risk of outcome assessment bias, if they were to classify
the trial outcome measures according to the definitions
in this protocol. To minimise this risk of bias, the classi-
fication of trial outcome measures will be conducted by
two authors (GG and JCJ) that have not taken part in
the data extraction (see section on ‘Outcome classifica-
tion’). If there is disagreement between GG and JCJ, a
fifth author (CG) will make the final decision. As neither
GG, JCJ, or CG have read the manuscripts or seen any
data from the included trials, they will be blinded to
group allocation, i.e. without knowledge of the number
of outcome events in the experimental and control
group.
Another limitation of this review is the potential lack
of ability to directly affect clinical decision making. The
primary analysis will rely on all included trials, irrespect-
ive of clinical setting or population. This increases the
probability of reaching a sufficient information size [80].
Due to the expectedly large clinical heterogeneity be-
tween included trials, however, it will be difficult to in-
terpret and extrapolate the results of the primary
analysis directly to a specific clinical setting. This issue
will be less of a problem in the subgroup analyses, but it
is unlikely that we will reach a sufficient information size
for these analyses, thus making it difficult to interpret
the results due to high risks of type I and II errors [80].
If the analysis reveals that the intervention has a bene-
ficial effect on any of the pre-specified outcomes, it will
rather serve as an encouragement to continue the con-
duct of randomised clinical trials within each clinical
setting, in order to reach a sufficient information size.
To disseminate this study, we intend to submit the re-
sults in one single manuscript, to a major international
medical journal. Furthermore, we intend to submit the
abstract for presentation at an international conference
within neonatal intensive care, as the authors are based
in this field.
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